AMLX
Amylyx Pharmaceuticals, Inc.NASDAQHealthcare$14.95+4.18%ClosedMarket Cap: $1.24B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.90
P/S
0.00
EV/EBITDA
-7.59
DCF Value
$2.30
FCF Yield
-9.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.5%
ROA
-43.5%
ROIC
-49.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-36.6M | $-33.0M | $-0.28 | — |
| FY 2025 | $0.00 | -Infinity% | $-153.3M | $-144.7M | $-1.53 | — |
| Q3 2025 | $0.00 | -Infinity% | $-36.0M | $-34.4M | $-0.37 | — |
| Q2 2025 | $0.00 | -Infinity% | $-42.9M | $-41.4M | $-0.46 | — |
| Q1 2025 | $0.00 | NaN% | $-37.8M | $-35.9M | $-0.42 | — |
| Q4 2024 | $-665.0K | 100.0% | $-40.7M | $-37.5M | $-0.55 | — |
| FY 2024 | $87.4M | 51.8% | $-314.7M | $-301.7M | $-4.43 | — |
| Q3 2024 | $416.0K | -94.5% | $-75.7M | $-72.7M | $-1.07 | — |
| Q2 2024 | $-1.0M | 845.5% | $-53.4M | $-72.7M | $-1.07 | — |
| Q1 2024 | $88.6M | -31.3% | $-122.1M | $-118.8M | $-1.75 | — |
| Q4 2023 | $108.4M | 91.4% | $1.9M | $4.7M | $0.07 | — |
| FY 2023 | $380.8M | 93.3% | $38.8M | $49.3M | $0.70 | — |